{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,8]],"date-time":"2026-01-08T22:25:07Z","timestamp":1767911107018,"version":"3.49.0"},"reference-count":51,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2014,10,1]],"date-time":"2014-10-01T00:00:00Z","timestamp":1412121600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["mdconsult.com","theclinics.com","surgical.theclinics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Surgical Clinics of North America"],"published-print":{"date-parts":[[2014,10]]},"DOI":"10.1016\/j.suc.2014.07.004","type":"journal-article","created":{"date-parts":[[2014,8,7]],"date-time":"2014-08-07T14:17:32Z","timestamp":1407421052000},"page":"1003-1015","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":25,"title":["Locoregional Therapies in Melanoma"],"prefix":"10.1016","volume":"94","author":[{"given":"Andrea M.","family":"Abbott","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jonathan S.","family":"Zager","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.suc.2014.07.004_bib1","unstructured":"National Comprehensive Cancer Network. Melanoma. Version 3.2014. Available at: www.nccn.org. Accessed July 30, 2014."},{"key":"10.1016\/j.suc.2014.07.004_bib2","doi-asserted-by":"crossref","first-page":"6199","DOI":"10.1200\/JCO.2009.23.4799","article-title":"Final version of 2009 AJCC melanoma staging and classification","volume":"27","author":"Balch","year":"2009","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.suc.2014.07.004_bib3","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1245\/ASO.2005.05.025","article-title":"Predictors and natural history of in-transit melanoma after sentinel lymphadenectomy","volume":"12","author":"Pawlik","year":"2005","journal-title":"Ann Surg Oncol"},{"key":"10.1016\/j.suc.2014.07.004_bib4","doi-asserted-by":"crossref","first-page":"366","DOI":"10.6004\/jnccn.2012.0036","article-title":"Melanoma","volume":"10","author":"Coit","year":"2012","journal-title":"J\u00a0Natl Compr Canc Netw"},{"key":"10.1016\/j.suc.2014.07.004_bib5","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1007\/s11912-013-0333-5","article-title":"Current treatment of locoregional recurrence of melanoma","volume":"15","author":"Squires","year":"2013","journal-title":"Curr Oncol Rep"},{"key":"10.1016\/j.suc.2014.07.004_bib6","doi-asserted-by":"crossref","first-page":"1063","DOI":"10.1002\/(SICI)1097-0142(20000301)88:5<1063::AID-CNCR17>3.0.CO;2-E","article-title":"Analysis of prognosis and disease progression after local recurrence of melanoma","volume":"88","author":"Dong","year":"2000","journal-title":"Cancer"},{"key":"10.1016\/j.suc.2014.07.004_bib7","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1097\/01.sla.0000094440.50547.1d","article-title":"Is sentinel lymph node mapping indicated for isolated local and in-transit recurrent melanoma?","volume":"238","author":"Yao","year":"2003","journal-title":"Ann Surg"},{"key":"10.1016\/j.suc.2014.07.004_bib8","first-page":"1435","article-title":"Efficacy of repeat sentinel lymph node biopsy in patients who develop recurrent melanoma","volume":"21","author":"Beasley","year":"2014","journal-title":"J\u00a0Am Coll Surg"},{"key":"10.1016\/j.suc.2014.07.004_bib9","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1097\/00000658-195810000-00009","article-title":"Chemotherapy of cancer: regional perfusion utilizing an extracorporeal circuit","volume":"148","author":"Creech","year":"1958","journal-title":"Ann Surg"},{"key":"10.1016\/j.suc.2014.07.004_bib10","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1007\/s11864-004-0009-3","article-title":"Management of in-transit melanoma of the extremity with isolated limb perfusion","volume":"5","author":"Fraker","year":"2004","journal-title":"Curr Treat Options Oncol"},{"key":"10.1016\/j.suc.2014.07.004_bib11","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1016\/S0011-3840(99)80008-2","article-title":"Hyperthermic regional perfusion for melanoma and sarcoma of the limbs","volume":"36","author":"Fraker","year":"1999","journal-title":"Curr Probl Surg"},{"key":"10.1016\/j.suc.2014.07.004_bib12","doi-asserted-by":"crossref","first-page":"1237","DOI":"10.1001\/archsurg.139.11.1237","article-title":"Isolated limb perfusion for unresectable melanoma of the extremities","volume":"139","author":"Noorda","year":"2004","journal-title":"Arch Surg"},{"key":"10.1016\/j.suc.2014.07.004_bib13","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1002\/jso.10077","article-title":"Isolated limb perfusion for melanoma","volume":"79","author":"Kroon","year":"2002","journal-title":"J\u00a0Surg Oncol"},{"key":"10.1016\/j.suc.2014.07.004_bib14","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1097\/00000658-199612000-00011","article-title":"Isolated limb perfusion with tumor necrosis factor and melphalan for limb salvage in 186 patients with locally advanced soft tissue extremity sarcomas. The cumulative multicenter European experience","volume":"224","author":"Eggermont","year":"1996","journal-title":"Ann Surg"},{"key":"10.1016\/j.suc.2014.07.004_bib15","doi-asserted-by":"crossref","first-page":"4196","DOI":"10.1200\/JCO.2005.05.5152","article-title":"Randomized multicenter trial of hyperthermic isolated limb perfusion with melphalan alone compared with melphalan plus tumor necrosis factor: American College of Surgeons Oncology Group Trial Z0020","volume":"24","author":"Cornett","year":"2006","journal-title":"J\u00a0Clin Oncol"},{"issue":"Suppl 1","key":"10.1016\/j.suc.2014.07.004_bib16","first-page":"21","article-title":"Isolated perfusion of the limb with high-dose tumour necrosis factor-alpha (TNF-alpha), interferon-gamma (IFN-gamma) and melphalan for melanoma stage III. Results of a multi-centre pilot study","volume":"4","author":"Lienard","year":"1994","journal-title":"Melanoma Res"},{"key":"10.1016\/j.suc.2014.07.004_bib17","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1200\/JCO.1996.14.2.479","article-title":"Treatment of patients with melanoma of the extremity using hyperthermic isolated limb perfusion with melphalan, tumor necrosis factor, and interferon gamma: results of a tumor necrosis factor dose-escalation study","volume":"14","author":"Fraker","year":"1996","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.suc.2014.07.004_bib18","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1080\/02656730701805520","article-title":"Toxicities associated with hyperthermic isolated limb perfusion and isolated limb infusion in the treatment of melanoma and sarcoma","volume":"24","author":"Moller","year":"2008","journal-title":"Int J Hyperthermia"},{"key":"10.1016\/j.suc.2014.07.004_bib19","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1016\/0277-5379(82)90235-8","article-title":"Dosimetry in isolation perfusion of the limbs by assessment of perfused tissue volume and grading of toxic tissue reactions","volume":"18","author":"Weiberdink","year":"1982","journal-title":"Eur J Cancer Clin Oncol"},{"key":"10.1016\/j.suc.2014.07.004_bib20","doi-asserted-by":"crossref","first-page":"1074","DOI":"10.1378\/chest.107.4.1074","article-title":"Systemic and hemodynamic effects of recombinant tumor necrosis factor alpha in isolation perfusion of the limbs","volume":"107","author":"Eggimann","year":"1995","journal-title":"Chest"},{"key":"10.1016\/j.suc.2014.07.004_bib21","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1001\/archsurg.1995.01430100057012","article-title":"Systemic leakage and side effects of tumor necrosis factor alpha administered via isolated limb perfusion can be manipulated by flow rate adjustment","volume":"130","author":"Sorkin","year":"1995","journal-title":"Arch Surg"},{"key":"10.1016\/j.suc.2014.07.004_bib22","doi-asserted-by":"crossref","first-page":"2195","DOI":"10.1245\/s10434-008-9988-9","article-title":"Isolated limb infusion for in-transit malignant melanoma of the extremity: a well-tolerated but less effective alternative to hyperthermic isolated limb perfusion","volume":"15","author":"Beasley","year":"2008","journal-title":"Ann Surg Oncol"},{"key":"10.1016\/j.suc.2014.07.004_bib23","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1016\/j.jamcollsurg.2011.03.013","article-title":"Current trends in regional therapy for melanoma: lessons learned from 225 regional chemotherapy treatments between 1995 and 2010 at a single institution","volume":"213","author":"Raymond","year":"2011","journal-title":"J\u00a0Am Coll Surg"},{"key":"10.1016\/j.suc.2014.07.004_bib24","doi-asserted-by":"crossref","first-page":"3003","DOI":"10.1245\/s10434-008-9954-6","article-title":"Outcomes following isolated limb infusion for melanoma. A 14-year experience","volume":"15","author":"Kroon","year":"2008","journal-title":"Ann Surg Oncol"},{"key":"10.1016\/j.suc.2014.07.004_bib25","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1002\/(SICI)1098-2388(199804\/05)14:3<238::AID-SSU8>3.0.CO;2-9","article-title":"Isolated limb infusion with cytotoxic agents: a simple alternative to isolated limb perfusion","volume":"14","author":"Thompson","year":"1998","journal-title":"Semin Surg Oncol"},{"key":"10.1016\/j.suc.2014.07.004_bib26","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1016\/j.jamcollsurg.2008.12.019","article-title":"A\u00a0multi-institutional experience of isolated limb infusion: defining response and toxicity in the US","volume":"208","author":"Beasley","year":"2009","journal-title":"J\u00a0Am Coll Surg"},{"key":"10.1016\/j.suc.2014.07.004_bib27","doi-asserted-by":"crossref","first-page":"2570","DOI":"10.1245\/s10434-009-0563-9","article-title":"Predictive factors of regional toxicity and serum creatine phosphokinase levels after isolated limb infusion for melanoma: a multi-institutional analysis","volume":"16","author":"Santillan","year":"2009","journal-title":"Ann Surg Oncol"},{"key":"10.1016\/j.suc.2014.07.004_bib28","doi-asserted-by":"crossref","first-page":"1637","DOI":"10.1245\/s10434-011-2151-z","article-title":"A\u00a0multi-institutional experience of repeat regional chemotherapy for recurrent melanoma of extremities","volume":"19","author":"Chai","year":"2012","journal-title":"Ann Surg Oncol"},{"key":"10.1016\/j.suc.2014.07.004_bib29","doi-asserted-by":"crossref","first-page":"1932","DOI":"10.1002\/cncr.24220","article-title":"Efficacy of repeat isolated limb infusion with melphalan and actinomycin D for recurrent melanoma","volume":"115","author":"Kroon","year":"2009","journal-title":"Cancer"},{"key":"10.1016\/j.suc.2014.07.004_bib30","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1097\/00000658-197410000-00029","article-title":"BCG immunotherapy of malignant melanoma: summary of a seven-year experience","volume":"180","author":"Morton","year":"1974","journal-title":"Ann Surg"},{"key":"10.1016\/j.suc.2014.07.004_bib31","doi-asserted-by":"crossref","first-page":"1692","DOI":"10.1002\/cncr.20166","volume":"100","author":"Agarwala","year":"2004","journal-title":"Cancer"},{"key":"10.1016\/j.suc.2014.07.004_bib32","doi-asserted-by":"crossref","first-page":"1620","DOI":"10.1038\/sj.bjc.6601320","article-title":"Phase II trial of intralesional therapy with interleukin-2 in soft-tissue melanoma metastases","volume":"89","author":"Radny","year":"2003","journal-title":"Br J Cancer"},{"issue":"Suppl","key":"10.1016\/j.suc.2014.07.004_bib33","article-title":"Consequential administration of intralesional (intratumoral) GM-CSF and IL-2 in the management of metastatic and primary invasive cutaneous melanoma","author":"Elias","year":"2013","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.suc.2014.07.004_bib34","doi-asserted-by":"crossref","first-page":"e68561","DOI":"10.1371\/journal.pone.0068561","article-title":"Intralesional injection of rose bengal induces a systemic tumor-specific immune response in murine models of melanoma and breast cancer","volume":"8","author":"Toomey","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.suc.2014.07.004_bib35","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1097\/CMR.0b013e32831328c7","article-title":"Chemoablation of metastatic melanoma using intralesional rose Bengal","volume":"18","author":"Thompson","year":"2008","journal-title":"Melanoma Res"},{"key":"10.1016\/j.suc.2014.07.004_bib36","unstructured":"Agarwala SS, Thompson JF, Smithers BM, et\u00a0al. Locoregional disease control in metastatic melanoma: exploratory analysis from phase 2 testing of intralesional rose Bengal. ECCO-ESMO-ESTRO Congress. Amsterdam, September 2013 [abstract: 3755]."},{"issue":"Suppl","key":"10.1016\/j.suc.2014.07.004_bib37","first-page":"15s","article-title":"Chemoablation of metastatic melanoma with rose bengal (PV-10)","volume":"28","author":"Agarwala","year":"2010","journal-title":"J\u00a0Clin Oncol"},{"issue":"Suppl","key":"10.1016\/j.suc.2014.07.004_bib38","article-title":"Chemoablation of melanoma with intralesional rose Bengal (PV-10)","author":"Agarwala","year":"2009","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.suc.2014.07.004_bib39","doi-asserted-by":"crossref","first-page":"5763","DOI":"10.1200\/JCO.2009.24.3675","article-title":"Phase II clinical trial of a granulocyte-macrophage colony-stimulating factor-encoding, second-generation oncolytic herpesvirus in patients with unresectable metastatic melanoma","volume":"27","author":"Senzer","year":"2009","journal-title":"J\u00a0Clin Oncol"},{"issue":"Suppl","key":"10.1016\/j.suc.2014.07.004_bib40","article-title":"OPTiM: a randomized phase 3 trial of talimogene laherparepvec (T-VEC) vs subcutaneous (SC) granulocyte-macrophage colony-stimulating factor (GM-CSF) for the treatment (tx) of unresected stage IIIB\/C and IV melanoma","volume":"31","author":"Andtbacka","year":"2013","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.suc.2014.07.004_bib41","unstructured":"Andtbacka RH, Ross MI, Delman K, et\u00a0al. Responses of injected and uninjected lesions to intralesional talimogene laherparepvec (T-VEC) in the OPTiM study and the contribution of surgery to response. Society of Surgical Oncology Annual Meeting. Phoenix, March 2014."},{"key":"10.1016\/j.suc.2014.07.004_bib42","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1111\/j.1524-4725.2012.02362.x","article-title":"Melanoma in situ treated successfully using imiquimod after nonclearance with surgery: review of the literature","volume":"38","author":"Ellis","year":"2012","journal-title":"Dermatol Surg"},{"key":"10.1016\/j.suc.2014.07.004_bib43","first-page":"1","article-title":"Novel dermatologic uses of the immune response modifier imiquimod 5% cream","volume":"7","author":"Berman","year":"2002","journal-title":"Skin Therapy Lett"},{"key":"10.1016\/j.suc.2014.07.004_bib44","doi-asserted-by":"crossref","first-page":"1641","DOI":"10.1007\/s10637-011-9717-2","article-title":"Topical treatment of cutaneous metastases of malignant melanoma using combined imiquimod and 5-fluorouracil","volume":"30","author":"Florin","year":"2012","journal-title":"Invest New Drugs"},{"key":"10.1016\/j.suc.2014.07.004_bib45","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1002\/jso.23506","article-title":"Topical immunotherapy with diphencyprone for in transit and cutaneously metastatic melanoma","volume":"109","author":"Damian","year":"2014","journal-title":"J\u00a0Surg Oncol"},{"key":"10.1016\/j.suc.2014.07.004_bib46","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1016\/0360-3016(91)90053-7","article-title":"Fraction size in external beam radiation therapy in the treatment of melanoma","volume":"20","author":"Sause","year":"1991","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.suc.2014.07.004_bib47","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1016\/S0360-3016(99)00066-8","article-title":"Palliative radiotherapy for recurrent and metastatic malignant melanoma: prognostic factors for tumor response and long-term outcome: a 20-year experience","volume":"44","author":"Seegenschmiedt","year":"1999","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.suc.2014.07.004_bib48","doi-asserted-by":"crossref","first-page":"1791","DOI":"10.1002\/cncr.22988","article-title":"A\u00a0higher radiotherapy dose is associated with more durable palliation and longer survival in patients with metastatic melanoma","volume":"110","author":"Olivier","year":"2007","journal-title":"Cancer"},{"key":"10.1016\/j.suc.2014.07.004_bib49","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1148\/radiology.164.3.3112864","article-title":"Malignant melanoma: analysis of dose fractionation in radiation therapy","volume":"164","author":"Konefal","year":"1987","journal-title":"Radiology"},{"issue":"8","key":"10.1016\/j.suc.2014.07.004_bib50","doi-asserted-by":"crossref","first-page":"780","DOI":"10.1002\/jso.23590","article-title":"Australian multi-center experience outside of the Sydney Melanoma Unit of isolated limb infusion chemotherapy for melanoma","volume":"109","author":"Coventry","year":"2014","journal-title":"J\u00a0Surg Oncol"},{"issue":"4","key":"10.1016\/j.suc.2014.07.004_bib51","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.1245\/s10434-012-2782-8","article-title":"Isolated limb infusion in a series of over 100 infusions: a single-center experience","volume":"20","author":"Wong","year":"2013","journal-title":"Ann Surg Oncol"}],"container-title":["Surgical Clinics of North America"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0039610914001030?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0039610914001030?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,8,13]],"date-time":"2019-08-13T13:28:14Z","timestamp":1565702894000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0039610914001030"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,10]]},"references-count":51,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2014,10]]}},"alternative-id":["S0039610914001030"],"URL":"https:\/\/doi.org\/10.1016\/j.suc.2014.07.004","relation":{},"ISSN":["0039-6109"],"issn-type":[{"value":"0039-6109","type":"print"}],"subject":[],"published":{"date-parts":[[2014,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Locoregional Therapies in Melanoma","name":"articletitle","label":"Article Title"},{"value":"Surgical Clinics of North America","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.suc.2014.07.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2014 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}